Raymond James Financial Comments on TSE:MDP Q1 Earnings

Key Points

• Raymond James Financial expects Medexus Pharmaceuticals to earn $0.15 per share in Q1 2027, slightly below the current full-year earnings estimate of $0.16 per share.
• Alliance Global Partners upgraded Medexus Pharmaceuticals to a "strong-buy" rating, contributing to an average stock rating of "Buy" with a consensus price target of C$5.49.
• As of the latest trading session, Medexus shares reached C$2.82, with a market capitalization of C$63.13 million and a twelve-month price range between C$1.71 and C$5.56.

Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Equities research analysts at Raymond James Financial issued their Q1 2027 earnings per share (EPS) estimates for Medexus Pharmaceuticals in a report released on Wednesday, August 13th. Raymond James Financial analyst M. Freeman expects that the company will post earnings per share of $0.15 for the quarter. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share.

Separately, Alliance Global Partners raised Medexus Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 11th. Four equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of C$5.49.

Medexus Pharmaceuticals Stock Performance

TSE:MDP traded up C$0.15 during mid-day trading on Friday, hitting C$2.96. The company had a trading volume of 42,067 shares, compared to its average volume of 72,844. Medexus Pharmaceuticals has a fifty-two week low of C$1.71 and a fifty-two week high of C$5.56. The business's fifty day moving average is C$2.92 and its two-hundred day moving average is C$2.79. The firm has a market cap of C$66.27 million, a P/E ratio of 14.15 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.